GlassScriptPhysician profile
Ruslan Garcia
NPI 1659802445
$2,469.40
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.75 · 2021: $505 · 2022: $947 · 2023: $659 · 2024: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.34 | 2021-2024 | |
| Novo Nordisk INC | $293.63 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $151.59 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $134.98 | 2021-2023 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $119.94 | 2021-2024 | Prolia, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $116.11 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $107.15 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $68.16 | 2022-2023 | |
| Indivior INC. | $65.77 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $58.95 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Xeris Pharmaceuticals, INC. | $58.06 | 2023-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $31.07 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $28.80 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $18.99 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.81 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruslan Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.